Production of genome-edited pluripotent stem cells and mice by CRISPR/Cas

Endocr J. 2016;63(3):213-9. doi: 10.1507/endocrj.EJ15-0734. Epub 2016 Jan 6.

Abstract

Clustered regularly at interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) nucleases, so-called CRISPR/Cas, was recently developed as an epoch-making genome engineering technology. This system only requires Cas9 nuclease and single-guide RNA complementary to a target locus. CRISPR/Cas enables the generation of knockout cells and animals in a single step. This system can also be used to generate multiple mutations and knockin in a single step, which is not possible using other methods. In this review, we provide an overview of genome editing by CRISPR/Cas in pluripotent stem cells and mice.

Publication types

  • Review

MeSH terms

  • Animals
  • CRISPR-Cas Systems*
  • Embryonic Stem Cells / cytology
  • Embryonic Stem Cells / enzymology
  • Embryonic Stem Cells / metabolism
  • Gene Editing* / trends
  • Gene Knock-In Techniques / trends
  • Gene Knockout Techniques / trends
  • Humans
  • Induced Pluripotent Stem Cells / cytology
  • Induced Pluripotent Stem Cells / enzymology
  • Induced Pluripotent Stem Cells / metabolism
  • Mice
  • Mice, Knockout / genetics*
  • Mice, Knockout / metabolism
  • Models, Genetic*
  • Mosaicism
  • Pluripotent Stem Cells / cytology*
  • Pluripotent Stem Cells / enzymology
  • Pluripotent Stem Cells / metabolism